mRNA-loaded are a promising cancer vaccine platform, but delivery, targeting, immune activation, and manufacturing remain central hurdles.
Evidence
This review synthesizes LNP design principles, combination strategies, clinical signals including KEYNOTE-942, and future formulation and regulatory directions for mRNA cancer vaccines.
Caveat
The abstract highlights emerging efficacy signals but mostly reviews design and translational evidence rather than proving broad clinical benefit across cancers.
Simplified
Cancer vaccines are promising, but clinical translation is constrained by inefficient antigen delivery and suboptimal immune activation. (LNPs)-validated for potency and safety in COVID-19 -offer a versatile, scalable, and immunogenic platform. Key barriers persist: precise targeting of tumors or lymphoid tissues, efficient intracellular mRNA release, and the immunosuppressive tumor microenvironment. This review synthesizes design principles for mRNA-loaded LNPs, emphasizing lipid chemistry, organ-selective biodistribution, and nano-engineering strategies that strengthen antigen presentation and T-cell priming. We also examine combination approaches with checkpoint blockade, chemotherapy-induced immunogenic cell death, and molecular adjuvants. Clinically, signals of efficacy are emerging-most notably the KEYNOTE-942 study, in which mRNA-4157 combined with pembrolizumab showed a sustained improvement in recurrence-free survival at 5 years compared with pembrolizumab alone-highlighting both the potential and the remaining questions for this modality. Finally, we outline manufacturing and regulatory considerations and map future directions-including thermostable formulations, self-amplifying RNA, and AI-guided lipid discovery-to address translational bottlenecks and expand global access to LNP-based cancer vaccines.
Key numbers
74.8%
Improvement in Recurrence-Free Survival
-4157 plus pembrolizumab vs. pembrolizumab alone
70
Active Interventional Trials
Ongoing trials evaluating -based cancer vaccines
13.4 months
Median Disease-Free Survival
Observed in responders to autogene cevumeran for pancreatic ductal adenocarcinoma
Full Text
We can’t show the full text here under this license.
